Expression from the human parvovirus B 19p6 promoter fused to the firefly luciferase (' Luc') reporter gene was evaluated in a non-erythroid human nasopharyngeal carcinoma cell line, KB, and a human megakaryocytic leukaemia cell line, MB-02, known to become permissive for B19 replication following erythroid-differentiation. The B19p6-Luc construct was introduced into KB and MB-02 cells, both in undifferentiated and differentiated states, either via DNA-mediated transfection, or via infection with recombinant adeno-associated virus 2 (AAV), a non-pathogenic human parvovirus known to possess a broad host-range. Although Luc activity was readily detected in KB cells following transfection of the B 19p6-Luc plasmid DNA, no expression from the B 19p6 promoter was observed following infection with recombinant virus. In addition, transfection of the reporter plasmid resulted in high-level expression of Luc in differentiated but not in undifferentiated MB-02 cells. However, no Luc activity was detected, even in differentiated MB-02 cells, following infection with recombinant virus. Further studies with an additional recombinant as well as wild-type (wt) AAV revealed that MB-02 cells were non-permissive for AAV infection. A second human megakaryocytic leukaemia cell line, M07e, was likewise resistant to infection by recombinant as well as wt AAV. Taken together, these studies identify the first human cell type that cannot be infected by AAV.
Introduction
Human parvovirus B19 was discovered serendipitously in the serum of an asymptomatic blood donor (Cossart et al., 1975) , and is now known to be the causative agent of a variety of clinical disorders that include transient aplastic crises associated with various haemolytic anaemias Serjeant et al., 1981 ; Saarinen et al., 1986) , erythema infectiosum (Anderson et al., 1983) , thrombocytopenia (Anderson et al., 1985) , chronic bone marrow failure and hydrops fetalis (Brown et al., 1984) . B19 exhibits a remarkable tissue-tropism for the erythroid lineage in human haematopoietic progenitor cells. So far, only primary cells from human bone marrow (Ozawa et al., , 1987b Srivastava & Lu, 1988; Srivastava et al., 1990) , fetal liver (Yaegashi et al., 1989) , peripheral blood (Schwarz et al., 1992) and umbilical cord blood have been shown to support B19 replication in vitro. Recently, we (Munshi et al., 1993) and others (Shimomura et al., 1992) have identified megakaryocytic leukaemia cell lines which become permissive for BI9 replication upon treatment with erythropoietin (Epo). More recently, it has been suggested that erythrocyte P antigen (globoside) plays a vital role as a cellular receptor for selective infection of erythroid progenitor cells by B19 (Brown et al., 1993) . However, a number of non-erythroid human cell types that express this receptor are non-permissive for B19 replication (Srivastava et al., 1990; Brown et al., 1994) , suggesting that additional features of B19 underlie the molecular control of virus infectivity subsequent to P antigen receptor-mediated entry into human erythroid progenitor ceils.
The B19 genome contains a non-structural (NS-1) gene encoding the NS-1 protein that is required for virus replication, and a structural gene (Cap) In order to resolve this apparent paradox, we examined expression from B 19p6 and B 19p44 promoters following DNA-mediated transfections as well as recombinantvirus infections of a non-erythroid human nasopharyngeal carcinoma cell line, KB, that is nonpermissive for B19 replication. We also utilized a human megakaryocytic leukaemia cell line, MB-02 (Morgan et al., 1991), that can be induced to undergo erythroiddifferentiation following treatment with Epo, and that we have documented to become permissive for B19 replication (Munshi et al., 1993) . MB-02 cells thus offered a useful system to evaluate B19 promoter functions under both permissive and non-permissive conditions. In this report, we provide evidence that whereas abundant expression from the B19p6 promoter occurs following DNA-mediated transfections, little expression from this promoter occurs in the context of a recombinant AAV genome in non-erythroid cells known to be permissive for AAV infection. The B19p44 promoter, on the other hand, is transcriptionally inactive in either form. We also report that the human megakaryocytic leukaemia cells are naturally resistant to infection by recombinant as well as wt AAV, and suggest that AAV infection of human cells is receptor-mediated.
Methods
Cells and viruses. The human nasopharyngeal carcinoma cell line KB was obtained from A.C. Antony, Indiana University School of Medicine (Indianapolis, Ind., USA), and the human erythroleukaemia cell line K562 was purchased from the ATCC. Cultures were maintained in Iscove's modified Dulbecco's medium (IMDM; Sigma) supplemented with 10% fetal bovine serum (FBS) as previously described (Nahreini & Srivastava, 1989 , 1992 . The human megakaryocytic leukaemia cell lines MB-02 and M07e were kindly provided by D. A. Morgan, Hahnemann University (Philadelphia, Pa., USA), and H. E. Broxmeyer (Indiana University School of Medicine, Indianapolis, Ind., USA), respectively, and maintained as previously described (Morgan et aL, 1991 ; Hendrie et al., 1991) . Erythroid-differentiation of MB-02 cells was induced by addition of Epo (Toyobo Co.) as previously described (Munshi et al., 1993) . Normal human bone marrow cells were obtained from healthy volunteers through a protocol approved by the Institutional Review Board. Human adeno-associated virus 2 (AAV) was kindly supplied by K. I. Berns, Cornell University Medical College (New York, NY, USA), and human adenovirus type 2 (Ad2) was obtained from K. H. Fife, Indiana University School of Medicine (Indianapolis, Ind., USA). Virus stocks were grown and maintained as previously described (Srivastava, 1987; Nahreini & Srivastava, 1989 , 1992 .
Construction of the recombinant AA V plasmids and virions. Plasmids pTwu.G1 (Nahreini et al., 1993 ), pRSVL (deWet et al., 1987 , pYTI03 (Shade et al., 1986) , pWN-1 (Nahreini et al., 1993) , pB19p6 (Zhou et al., 1994) and pWP-19 (Nahreini et al., 1993) used in the present studies have been described previously. The B 19p6 promoter region used in the present studies was isolated from plasmid pYT103 as an AhalII HinclI fragment (nt 199-423) . The general overall strategy to construct the recombinant AAV genomes containing a gene for luciferase ('Luc') under the control of the herpesvirus thymidine kinase (TK) promoter (pWM-1), the B19p6 promoter (pSP-6) and the B19p44 promoter (pMW-5), respectively, is depicted in Fig. 1 . These plasmids were used to generate recombinant AAV virions, vTKp-Luc, vBl9p6-Luc and vB 19p44-Luc, respectively. Virus titres were determined on quantitative DNA slot-blots using a z~P-labelled Luc-specific DNA probe as previously described (Srivastava et al., , 1990 .
Plasmid transfections, virus infections and reporter gene expression assays. DNA transfections were carried out using lipofectamine reagent under conditions specified by the supplier (Gibco-BRL). All transfection experiments were performed at least twice, and in the presence of a constant amount of a recombinant plasmid (CMVp-LacZ) containing a cytomegalovirus (CMV) promoter-driven fl-galactosidase ('LacZ') gene to normalize transfection efficiency. Unless otherwise indicated, all infections with recombinant AAV were carried out at an m.o.i, of 1 at 37 °C for 1 h. Luciferase assays were done in duplicate 48 h post-transfection/infection using the Promega Luciferase System with a Lumat LB 9501 Berthold luminometer. In some experiments with infection with recombinant AAV containing the CMV promoterdriven LacZ gene, cells were processed for in situ staining for LacZ expression. Briefly, cells were fixed using formaldehyde (2%) and glutaraldehyde (0.2 %) fixative in PBS and subsequently stained with X-Gal and observed under a Nikon inverted light microscope.
AA V replication assays. These were done as described previously (Samulski et al., 1987; Nahreini & Srivastava, 1989 , 1992 . The wt AAV and Ad2 virions were used at m.o.i, values of 1 and 10, respectively, as described above. Cells were harvested 72 h postinfection; low-M r DNA was then isolated as described by Hirt (1967) , and analysed on Southern blots using a 3~P-labelled AAV-specific DNA probe as described previously (Nahreini et al., 1993) . Genes for resistance to ampicillin (" Ap R') or neomycin ('neo R') were also inserted in these plasmids in order to generate the recombinant AAV virions with high efficiency (Muzyczka, 1992; Nahreini et al., 1992) . Each of the recombinant AAV genomes was rescued from its respective plasmid and packaged separately into AAV virions, designated vTKp-Luc, vB 19p6-Luc and vB 19p44-Luc, respectively, by the methods described previously Zhou et al., 1993; Ponnazhagan et al., 1994) .
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Results
Lack of expression from the B19p6 promoter following recombinant AA V-mediated transduction of nonervthroid human cells
We have previously reported that expression from the B19p6 promoter is largely restricted to primary human haematopoietic cells in the erythroid lineage following infection with a recombinant AAV-B19 hybrid virus . However, from plasmid transfection studies, Liu et al. (1991) concluded that expression from the B19p6 promoter occurs indiscriminately in non-permissive cells. In order to resolve this issue, we performed DNA-mediated transfections with equivalent amounts (3 gg of the test plasmid plus 1 gg of the CMVp-LacZ plasmid to control for transfection efficiency), as well as recombinant AAV infections (m.o.i. of 1) in non-erythroid human KB cells with the B19p6-Luc gene as a reporter. Mock-transfections/infections as well as transfections/infections with the TKp-Luc and the B19p44-Luc constructs were also carried out as appropriate controls. These results are shown in Fig. 2 . It is evident that the TK promoter-driven expression of Luc gene was exceeded by that from the B19p6 promoter following DNA-mediated transfections (Fig. 2a) . However, no Luc activity from the latter promoter could be detected following recombinant virus infection, although expression from the TK promoter was still detectable under identical conditions (Fig. 2b) . Similar results were obtained at m.o.i, values of 10 and 100, indicating that the observed lack of expression was not due to the limiting viral titres (data not shown). These results indicate that expression from the B19p6 promoter does not occur in non-erythroid cells in the context of a parvoviral genome. This observation has been substantiated in an additional non-erythroid cell line, HeLa, transduced with recombinant AAV-B19p6-Luc virions as well as with different recombinant AAV containing the neomycin-resistance ('neo R') and LacZ genes, respectively, under the control of the B 19p6 promoter (data not shown). No expression from the B19p44 promoter, in either the plasmid or the virus form, was detected suggesting that this promoter is non-functional, an observation consistent with previous reports (Liu et al., 1991; Brown et al., 1994) .
Lack of expression from the B19p6 promoter in human erythroid cells that are non-permissive for B19 replication
We next examined expression from the B19p6 promoter in a human erythroid cell line, K562, that has previously been shown to be non-permissive for B19 replication , and in a human granulocytemacrophage colony-stimulating factor (GM-CSF)-dependent megakaryocytic leukaemia cell line, MB-02, that can be induced to undergo erythroid-differentiation following treatment with erythropoietin (Epo), and which we have documented to become permissive for B19 replication only upon erythroid-differentiation (Munshi et al., 1993) . Under identical conditions, equivalent numbers of K562 and MB-02 (both undifferentiated and erythroid-differentiated) cells were mockinfected or infected at 1 m.o.i, each of recombinant vTKp-Luc, vB19p6-Luc and vB19p44-Luc virions, respectively, and analysed for Luc gene expression as described above. These results are shown in Fig. 3 . It is evident that whereas significant expression of the Luc gene occurred from the TK promoter in K562 cells, no significant activity either from the B19p6 or the B19p44 promoters could be detected (Fig. 3 a) . It is intriguing to note that no expression from any of these promoters occurred in either undifferentiated (Fig. 3 b) or erythroiddifferentiated (Fig. 3 c) MB-02 cells. The following sets of experiments were carried out to further explore this observation.
Human megakaryocytic leukaemia cells are nonpermissive for infection by recombinant as well as wildtype AA V
In addition to MB-02 cells, we examined a second human megakaryocytic leukaemia cell line, M07e, for susceptibility to infection by recombinant AAV. This was done by using recombinant AAV stocks containing the Luc gene under the control of the CMV promoter. Prior to these analyses, high level expression from the CMV promoter in these cells had been demonstrated by use of plasmid DNA transfections to ensure the functional activity of this promoter (data not shown, but see Fig. 8 ). Equivalent numbers of K562, MB-02 and M07e cells were mock-infected or infected with vCMVp-Luc virions at an m.o.i, of 1, and analysed for expression of the reporter gene as described in Methods. These results are presented in Fig. 4 . It is evident that whereas a significantly high level of Luc activity was detected in recombinant virus-transduced K562 cells, there was no detectable activity in MB-02 or M07e cells.
Since it remained possible that expression of the transduced Luc gene was below the detection limit, we next examined whether wt AAV could undergo replication in these cells in the presence of a helper-virus, such as adenovirus (Ad2). Previous studies have demonstrated abundant and easily detectable replication of viral replicative DNA intermediates in permissive human cells, such as HeLa, in the presence of Ad2 (Nahreini & Srivastava, 1989; Samulski et al., 1989) . Equivalent numbers of HeLa, K562, MB-02 and M07e cells were .oo .oo .oo o, mock-infected or infected with wt AAV at an m.o.i, of 1, in the presence or absence of 10 p.f.u, of Ad2 under identical conditions. Low-M r DNA samples were analysed for the presence of AAV DNA replicative intermediates on Southern blots as described in Methods. These results are shown in Fig. 5 . It is evident that whereas HeLa and K562 cells allowed high and low levels of replication, respectively, of AAV DNA, but only in the presence of Ad2, no viral replicative DNA intermediates were detected in either MB-02 or M07e cells. We were unable to detect AAV DNA replication in MB-02 and M07e cells even after prolonged exposure (data not shown). Although K562 cells are known to be susceptible to infection by recombinant AAV (Walsh et al., 1992; Ponnazhagan et al., 1994; Zhou et al., 1996) , the low level replication of AAV in these cells, and lack of AAV DNA replication in MB-02 and M07e cells, could also be because these cells are not infected by Ad2. This possibility was examined by re-probing the Southern blot shown in Fig. 5 with an Ad2-specific DNA probe. The results indicated abundant replication of Ad2 DNA in HeLa cells followed by that in K562 cells. Because low level replication of Ad2 DNA could also be detected in MB-02 and M07e cells (data not shown), these results further suggest that the absence of AAV DNA replicative DNA intermediates in these cells is not caused by lack of Ad2 infection. We next carried out infection experiments with a different recombinant AAV containing the LacZ gene under the control of the CMV promoter (vCMVp-LacZ) or the B19p6 promoter (vB19p6-LacZ). Equivalent numbers of K562, MB-02 and M07e cells were mockinfected or infected with recombinant vCMVp-LacZ, and examined for expression of the transduced gene. Similarly, equivalent numbers of normal human bone marrow (NBM) cells were mock-infected or infected with recombinant vCMVp-LacZ and vB19p6-LacZ, respectively, under identical conditions. The results shown in Fig. 6 (a) document that whereas LacZ gene expression was detected in approximately 6-10% of the recombinant virus-infected K562 (panel ii), no such activity could be detected in the infected MB-02 (panel iv) or M07e (panel vi) cells under identical conditions, suggesting that these megakaryocytic leukaemia cells were resistant to infection by AAV. On the other hand, the results shown in Fig. 6(b) show that expression of the LacZ gene, especially from the B19p6 promoter, did indeed occur in NBM cells known to be permissive for AAV infection as well as for B19 gene expression. These results further suggest that expression from the B19p6 promoter, in the context of a parvoviral genome, is restricted to primary human haematopoietic erythroid progenitor cells, and that AAV infection of human cells is receptor-mediated.
Expression from the B19p6 promoter in MB-02 cells during erythroid-differentiation
Since we were unable to transduce MB-02 cells with recombinant AAV, we next examined whether expression from the B19p6 promoter correlated with the differentiated state of these cells, especially because erythroiddifferentiated MB-02 cells support B19 gene expression and replication (Munshi et al., 1993) . Transfections were done with undifferentiated and erythroid-differentiated MB-02 cells with B19p6-Luc and B19p44-Luc plasmids, as well as plasmids containing an erythroid-specific enhancer element, HS-2, the DNase I-hypersensitive site 2 of the locus control region (LCR) of the human flglobin gene cluster (Tuan et al., 1989) to evaluate whether this enhancer could modulate expression from the B19 promoters in an erythroid cell-specific manner. K562 cells were also included in these experiments. These results are presented in Fig. 7 . It is evident that whereas the HS-2 enhancer element failed to elicit a response from the B19p44 promoter, expression from the B19p6 promoter was significantly increased by this enhancer in K562 cells (Fig. 7 a) . Interestingly, little expression from either of the two B19 promoters could be detected in undifferentiated MB-02 cells (Fig. 7b) . However, following erythroid-differentiation of these cells, significant expression from the B19p6 promoter, but not from the B19p44 promoter, was detected. Again, expression from the B19p6 promoter, but not from the B19p44 promoter, was further augmented by the HS-2 enhancer in these cells (Fig. 7 c) . We noted little difference in expression from the B19p6 promoter following DNA-mediated transfections with plasmids (pSP-5 and pSP-6 in Fig. 1 b) that either lacked or contained the AAV ITRs (Ponnazhagan et al., 1995) . Finally, we also wished to examine whether lack of expression from the B19p6 promoter in undifferentiated MB-02 cells was due to the presence of a non-specific inhibitor of Luc activity. Two additional recombinant plasmids containing the Luc gene under the control of the CMV and the SV40 promoters, respectively, were used in transfection experiments under identical conditions. The results of these experiments are shown in Fig.  8 . It is evident that abundant expression from these promoters occurred in K562 cells (Fig. 8 a) , as previously observed. Significant expression from the CMV promoter as well as the simian virus 40 (SV40) promoter, but not from the B19p6 promoter, with or without the upstream HS-2 enhancer element, also occurred in MB-02 cells (Fig. 8 b) . Taken together, these results indicate that the B19p6 promoter function may be regulated by factors expressed in cells undergoing erythroiddifferentiation, and that the observed lack of expression from the B19p6 promoter in undifferentiated cells is not due to the presence of a non-specific inhibitor in MB-02 cells.
Di scussi on
It is becoming increasingly clear that the remarkable tissue-tropism of human parvovirus B19 results from specific interactions of the viral genome with intracellular host factors (Wang et al., 1995; Ponnazhagan et al., 1995) . A cogent example of the crucial role intracellular factors play in tissue-tropism of minute virus of mice (MVM) has previously been reported (Spalholz & Tattersall, 1983) . Because indiscriminate activity from the B19p6 promoter has been reported by Liu et al. (1991) following DNA-mediated transfections in nonpermissive, established human cell lines, we sought to reexamine the role of expression from the viral promoter sequences in the erythroid-tropism of human parvovirus B19. In our recombinant virus-infection studies, we have thus far failed to obtain expression from this promoter of a number of different reporter genes such as Luc, LacZ and neo R in various established human cell lines. This is an important distinction because it has previously been reported that following DNA-mediated transfections, in the order of 500000 DNA molecules/cell are required to accomplish detectable expression of the transfected genes (Curiel et al., 1992) . Thus, in marked contrast to virus infections, DNA-mediated transfections may not be physiologically relevant, and all gene expression data obtained by the latter means must be interpreted with caution (Liu et al., 1991 (Liu et al., , 1992 .
The aforementioned problems notwithstanding, we were still able to obtain erythroid-specific expression from the B19p6 promoter in MB-02 cells. MB-02 cells offered a unique model system, primarily because the same culture system could be examined under both undifferentiated and erythroid-differentiated states, and we have previously reported that erythroid-differentiated MB-02 cells become permissive for expression of B19 genes as well as complete replication of the viral genome (Munshi et al., 1993) . Although expression from the B19p6 promoter could be detected in K562 cells, the significance of this observation is less clear both because wt B19 does not infect these cells, and because little expression from this promoter occurs in the context of a recombinant AAV genome. Expression from the B 19p6 promoter only in erythroid-differentiated MB-02 cells, on the other hand, may be important since it correlates well with replication of wt B19 in these cells (Munshi et al., 1993) . It is important to emphasize that in these experiments only a small fraction of MB-02 cells underwent successful erythroid-differentiation, as determined by morphological criteria, which could partially account for the observed low levels of expression from the B19p6 promoter compared to that in K562 cells. Thus, it is tempting to speculate that hitherto unknown intracellular factors present in erythroid-differentiated MB-02 cells contribute to the observed tropism of parvovirus B19. The fact that expression from the B19p6 promoter was significantly augmented by the erythroidspecific HS-2 enhancer, but only in erythroiddifferentiated MB-02 cells, further strengthens this hypothesis. Clearly, the potential role of other ubiquitous cis-acting elements in activation of the B 19p6 promoter in non-permissive K562 cells remains to be examined. Taking into account all available data, we propose that the remarkable erythroid-cell tropism of parvovirus B19 requires a dual level of specificity. First, erythrocyte P antigen is utilized as a cellular receptor for virus entry into erythroid cells, and to some extent into certain nonerythroid cells. Second, optimal transcriptional transactivation of the B19p6 promoter is accomplished by intracellular factors that are almost entirely restricted to human erythroid cells (Liu et al., 1992) . The proposed mechanism thus provides an explanation for the failure of B19 to undergo productive replication in nonerythroid cells that express the P antigen receptor. This proposal also helps to explain the retention of erythroidtropism of recombinant AAV-B19 hybrid virus ) that bypasses the P antigen receptor, and yet undergoes productive replication in an erythroid cell-specific manner (Wang et al., 1995) . Although analysis of the putative B19p44 promoter, either with or without the HS-2 enhancer element, did not reveal any functional activity in any of the cell lines tested, our recent studies document that it is possible to achieve transcriptional transactivation of the B19p44 promoter by adenovirus (Ponnazhagan et al., 1995) .
In our attempts to transduce MB-02 cells with recombinant AAV, we discovered that these cells were non-permissive for AAV infection. Several lines of evidence support this contention. No significant activity of any of the AAV-transduced reporter genes, such as Luc and LacZ, was evident in these cells. No G418-resistant clones of MB-02 cells could be obtained following AAV-mediated transduction with a selectable gene such as neo R. We also failed to detect wt AAV DNA replicative intermediates, even with co-infection with wt adenovirus. In addition, infection of MB-02 cells at both low and high m.o.i, values of wt AAV followed by serial passage failed to reveal the presence of integrated proviral AAV genomes on Southern blots. An additional human megakaryocytic leukaemia cell line, M07e, yielded identical results (data not shown). Thus, to our knowledge, this is the first instance that a human cell type has been identified that cannot be infected by AAV. 
